Abiomed (ABMD) Hits New Lifetime High

Trade-Ideas LLC identified Abiomed (ABMD) as a new lifetime high candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

Abiomed

(

ABMD

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Abiomed as such a stock due to the following factors:

  • ABMD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $123.3 million.
  • ABMD has traded 1,292 shares today.
  • ABMD is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ABMD with the Ticky from Trade-Ideas. See the FREE profile for ABMD NOW at Trade-Ideas

More details on ABMD:

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. ABMD has a PE ratio of 129. Currently there are 6 analysts that rate Abiomed a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Abiomed has been 591,300 shares per day over the past 30 days. Abiomed has a market cap of $4.7 billion and is part of the health care sector and health services industry. The stock has a beta of -0.20 and a short float of 8.8% with 2.73 days to cover. Shares are up 23.6% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Abiomed as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from the ratings report include:

  • The revenue growth greatly exceeded the industry average of 6.9%. Since the same quarter one year prior, revenues rose by 39.1%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • ABMD has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 5.48, which clearly demonstrates the ability to cover short-term cash needs.
  • Net operating cash flow has increased to $22.56 million or 23.51% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -16.79%.
  • The gross profit margin for ABIOMED INC is currently very high, coming in at 85.53%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 11.70% trails the industry average.
  • Compared to its closing price of one year ago, ABMD's share price has jumped by 66.27%, exceeding the performance of the broader market during that same time frame. Looking ahead, the stock's sharp rise over the last year has already helped drive it to a level which is relatively expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...